An Endogenous Inhibitor of Angiogenesis derived from a Transitional Cell Carcinoma: Clipped β2-Glycoprotein-I

[1]  E. Reefman.  Apoptotic cell clearance in Systemic Lupus Erythematosus (SLE) , 2006 .

[2]  K. McCrae,et al.  Annexin A2 mediates endothelial cell activation by antiphospholipid/anti-beta2 glycoprotein I antibodies. , 2005, Blood.

[3]  G. M. Iverson,et al.  Beta 2-Glycoprotein I binds factor XI and inhibits its activation by thrombin and factor XIIa: loss of inhibition by clipped beta 2-glycoprotein I. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[4]  R. Busse,et al.  Valproic acid inhibits angiogenesis in vitro and in vivo. , 2004, Molecular pharmacology.

[5]  H. Haupt,et al.  Über ein bisher unbekanntes niedermolekulares β2-Glubulin des Humanserums , 2004, Naturwissenschaften.

[6]  J. Folkman,et al.  Fundamental concepts of the angiogenic process. , 2003, Current molecular medicine.

[7]  S. Krilis,et al.  Anti-β2-glycoprotein I antibodies and the antiphospholipid syndrome , 2003 .

[8]  S. Krilis,et al.  Anti-beta(2)-glycoprotein I antibodies and the antiphospholipid syndrome. , 2003, Autoimmunity reviews.

[9]  Gerhard Jakse,et al.  Guidelines on bladder cancer. , 2002, European urology.

[10]  G. M. Iverson,et al.  Heparin Inhibits the Binding of β2-glycoprotein I to Phospholipids and Promotes the Plasmin-mediated Inactivation of This Blood Protein , 2002, The Journal of Biological Chemistry.

[11]  T. Otto,et al.  [Locally advanced or metastatic bladder carcinoma. Current aspects of therapy]. , 2001, Der Urologe. Ausg. A.

[12]  H. Rübben,et al.  Lokal fortgeschrittenes oder metastasiertes Harnblasenkarzinom Aktuelle Aspekte in der Therapie , 2001, Der Urologe A.

[13]  M. Samama,et al.  The Thrombophilic State in Cancer Patients , 2001, Acta Haematologica.

[14]  J. Folkman,et al.  Effect of antiangiogenic therapy on slowly growing, poorly vascularized tumors in mice. , 2001, Journal of the National Cancer Institute.

[15]  N. Ohkura,et al.  Highly increased plasma concentrations of the nicked form of beta(2) glycoprotein I in patients with leukemia and with lupus anticoagulant: measurement with a monoclonal antibody specific for a nicked form of domain V. , 2000, Journal of biochemistry.

[16]  J. Folkman,et al.  Efficacy of antiangiogenic therapy with TNP-470 in superficial and invasive bladder cancer models in mice. , 2000, Urology.

[17]  A. Eggermont,et al.  Angiostatin generation by human tumor cell lines: Involvement of plasminogen activators , 2000, International journal of cancer.

[18]  K. McCrae,et al.  High Affinity Binding of β2-Glycoprotein I to Human Endothelial Cells Is Mediated by Annexin II* , 2000, The Journal of Biological Chemistry.

[19]  H. Grossman,et al.  The utility of fibrin/fibrinogen degradation products in superficial bladder cancer. , 2000, The Urologic clinics of North America.

[20]  J. Folkman,et al.  The Hemostatic System as a Regulator of Angiogenesis* , 2000, The Journal of Biological Chemistry.

[21]  M Wilm,et al.  De Novo peptide sequencing by nanoelectrospray tandem mass spectrometry using triple quadrupole and quadrupole/time-of-flight instruments. , 2000, Methods in molecular biology.

[22]  William Arbuthnot Sir Lane,et al.  Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. , 1999, Science.

[23]  Conti,et al.  β2‐glycoprotein I (β2‐GPI) mRNA is expressed by several cell types involved in anti‐phospholipid syndrome‐related tissue damage , 1999 .

[24]  A. Tőkés,et al.  Tenascin expression and angiogenesis in breast cancers. , 1999, Pathology, research and practice.

[25]  P. D. de Groot,et al.  β2-Glycoprotein I Is Proteolytically Cleaved In Vivo upon Activation of Fibrinolysis , 1999, Thrombosis and Haemostasis.

[26]  R. Cote,et al.  Prognostic markers in bladder cancer: a contemporary review of the literature. , 1998, The Journal of urology.

[27]  N. Ohkura,et al.  Plasmin can reduce the function of human beta2 glycoprotein I by cleaving domain V into a nicked form. , 1998, Blood.

[28]  S. Campbell,et al.  Molecular mediators of angiogenesis in bladder cancer. , 1998, Cancer research.

[29]  A. Tincani,et al.  Apoptotic cell clearance in systemic lupus erythematosus: II. Role of β2-glycoprotein I , 1998 .

[30]  M. P. Fernández,et al.  Annexin gene structures and molecular evolutionary genetics , 1997, Cellular and Molecular Life Sciences CMLS.

[31]  A Sali,et al.  Site-directed mutagenesis of recombinant human beta 2-glycoprotein I identifies a cluster of lysine residues that are critical for phospholipid binding and anti-cardiolipin antibody activity. , 1996, Journal of immunology.

[32]  J. Folkman,et al.  Angiostatin induces and sustains dormancy of human primary tumors in mice , 1996, Nature Medicine.

[33]  G. Cai,et al.  Purification and characterization of an endothelial cell-viability maintaining factor from fetal bovine serum. , 1995, Biochimica et biophysica acta.

[34]  Lars Holmgren,et al.  Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.

[35]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[36]  G. Nelsestuen,et al.  Calcium and membrane-binding properties of monomeric and multimeric annexin II. , 1994, Biochemistry.

[37]  Lars Holmgren,et al.  Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.

[38]  K. Hajjar,et al.  An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II. , 1994, The Journal of biological chemistry.

[39]  H. Erickson,et al.  Cell surface annexin II is a high affinity receptor for the alternatively spliced segment of tenascin-C , 1994, The Journal of cell biology.

[40]  P. Hogg,et al.  Anticardiolipin Antibodies Block the Inhibition by β2-Glycoprotein I of the Factor Xa Generating Activity of Platelets , 1993, Thrombosis and Haemostasis.

[41]  R. Kellner,et al.  Annexin II is a major component of fusogenic endosomal vesicles , 1993, The Journal of cell biology.

[42]  C. Creutz.  The annexins and exocytosis. , 1992, Science.

[43]  F. Grant,et al.  Molecular cloning and sequence analysis of the cDNA encoding human apolipoprotein H (β2-Glycoprotein I)* , 1992, International journal of clinical & laboratory research.

[44]  H. Wu,et al.  Interaction of plasminogen and fibrin in plasminogen activation. , 1990, The Journal of biological chemistry.

[45]  T. Barbui,et al.  Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor , 1990, The Lancet.

[46]  C. Chesterman,et al.  Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[47]  J. Nimpf,et al.  Beta 2-glycoprotein-I (apo-H) inhibits the release reaction of human platelets during ADP-induced aggregation. , 1987, Atherosclerosis.

[48]  P. Bomans,et al.  Prothrombinase activity of human platelets is inhibited by β2-glycoprotein-I , 1986 .

[49]  R. Silverstein,et al.  Binding of plasminogen to extracellular matrix. , 1986, The Journal of biological chemistry.

[50]  P. Bomans,et al.  Prothrombinase activity of human platelets is inhibited by beta 2-glycoprotein-I. , 1986, Biochimica et biophysica acta.

[51]  H. Wurm.  beta 2-Glycoprotein-I (apolipoprotein H) interactions with phospholipid vesicles. , 1984, The International journal of biochemistry.

[52]  H. Brewer,et al.  Activation of human post heparin lipoprotein lipase by apolipoprotein H (beta 2-glycoprotein I). , 1980, Biochemical and biophysical research communications.

[53]  G. Kostner,et al.  Binding of beta 2-glycoprotein-I to intralipid: determination of the dissociation constant. , 1979, Biochemical and biophysical research communications.